Dana-Farber Cancer Institute is running a clinical trial to test drugs called Ibrutinib, Fludarabine, Cyclophosphamide and Rituximab to treat chronic lymphocytic leukemia. This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
The drugs are Ibrutinib, Fludarabine, Cyclophosphamide and Rituximab.
|Study Type :
||Interventional (Clinical Trial)
|Estimated Enrollment :
||Single Group Assignment
||None (Open Label)
||A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
|Actual Study Start Date :
|Estimated Primary Completion Date :
|Estimated Study Completion Date :
For enrollment please visit www.clinicaltrials.gov.